Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
- 1Department of Microbiology, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India
- 2Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India
- 3Division of Biochemistry, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India
- 4Department of Human Pathology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 5Department of Hospital Surgery, N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia
- 6Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States
- 7Department of Biotechnology, Acharya Institute of Technology, Bengaluru, India
- 8Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia
- 9Department of Sciences, Amrita School of Arts and Sciences, Amrita Vishwa Vidyapeetham, Mysuru, India
A Corrigendum on
Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
By Jain AS, Prasad A, Pradeep S, Dharmashekar C, Achar RR, Silina E, Stupin V, Amachawadi RG, Prasad SK, Pruthvish R, Syed A, Shivamallu C and Kollur SP (2021) Front. Oncol. 11:741326. doi: 10.3389/fonc.2021.741326
An author name was incorrectly spelled as “Silina Ekaterina”. The correct spelling is “Ekaterina Silina”.
An author name was incorrectly spelled as “Stupin Victor”. The correct spelling is “Victor Stupin”.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: non-small cell lung cancer, drug repurposing/repositioning, MAPK, targeted therapy, inhibitors
Citation: Jain AS, Prasad A, Pradeep S, Dharmashekar C, Achar RR, Silina E, Stupin V, Amachawadi RG, Prasad SK, Pruthvish R, Syed A, Shivamallu C and Kollur SP (2021) Corrigendum: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway. Front. Oncol. 11:822865. doi: 10.3389/fonc.2021.822865
Received: 26 November 2021; Accepted: 30 November 2021;
Published: 20 December 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Jain, Prasad, Pradeep, Dharmashekar, Achar, Silina, Stupin, Amachawadi, Prasad, Pruthvish, Syed, Shivamallu and Kollur. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ekaterina Silina, silinaekaterina@mail.ru; Chandan Shivamallu, chandans@jssuni.edu.in; Shiva Prasad Kollur, shivachemist@gmail.com
†These authors have contributed equally to this work and share first authorship